Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Elinafide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.84 |
| ▸ | HEXA | P06865 | 13/20 | 0.76 |
| ▸ | HEXB | P07686 | 13/20 | 0.76 |
| ▸ | OGA | O60502 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8396162 | 0.92 | SIRT1 (0.94) | SIRT1HEXAHEXBOGAMEN1 | |
| Elinafide SCHEMBL19067 | 0.92 | SIRT1 (1.00) | SIRT1HEXAHEXBOGAMEN1 | |
| Elinafide SCHEMBL6256967 | 0.92 | SIRT1 (1.00) | SIRT1HEXAHEXBOGAMEN1 | |
| Elinafide SCHEMBL29441732 | 0.92 | SIRT1 (1.00) | SIRT1HEXAHEXBOGAMEN1 | |
| SCHEMBL14524900 | 0.88 | SIRT1 (0.86) | SIRT1HEXAHEXBOGANR1I2 | |
| Bnipspd SCHEMBL13909975 | 0.87 | SIRT1 (0.91) | SIRT1HEXAHEXBOGAMEN1 | |
| SCHEMBL4408773 | 0.87 | HEXA (1.00) | SIRT1HEXAHEXBOGA | |
| SCHEMBL31011151 | 0.87 | HEXA (1.00) | SIRT1HEXAHEXBOGA | |
| SCHEMBL14028895 | 0.86 | SIRT1 (0.83) | SIRT1HEXAHEXBOGANR1I2 | |
| SCHEMBL13909963 | 0.86 | SIRT1 (0.94) | SIRT1HEXAHEXBOGAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-1954317-A2 | HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE | Genentech, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1817059-A2 | CONJUGATES OF 1,8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY | Genentech, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007064345-A9 | HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE | GENENTECH INC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007064345-A2 | HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE | GENENTECH, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060182751-A1 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006060533-A2 | CONJUGATES OF 1, 8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY | GENENTECH, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060182751-A1 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | CCNY, CCNI, MKI67 | SIRT1 1573/4885HEXA 3141/4885HEXB 3037/4885 |
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | SIRT1 2328/4885HEXA 3422/4885HEXB 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.